Brain peptides in Alzheimer's disease - pathophysiology and therapeutic advances - PubMed
12 hours ago
- #Alzheimer's disease
- #Therapeutic advances
- #Brain peptides
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with cognitive decline and memory impairment.
- Key neuropathological features include amyloid-β (Aβ) plaques and neurofibrillary tangles from hyperphosphorylated tau.
- Peptides play a dual role in AD: pathogenic peptides like Aβ oligomers drive neurodegeneration, while neuropeptides offer neuroprotection.
- Advances in peptide chemistry enable therapeutic strategies like aggregation inhibitors and neuropeptide analogues.
- Peptide-based therapies target pathways such as proteostasis, insulin signaling, neurotrophic support, and microglial activation.
- Challenges in clinical translation include blood-brain barrier penetration, metabolic stability, and off-target effects.
- Next-generation peptide therapeutics may improve AD diagnosis, prevention, and treatment.